trending Market Intelligence /marketintelligence/en/news-insights/trending/ugs4ftumble9edevppmzfg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Court dismisses Amgen patent case against Coherus' biosimilar

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Court dismisses Amgen patent case against Coherus' biosimilar

A U.S. federal court dismissed Amgen Inc.'s patent lawsuit against Coherus Biosciences Inc. for failing to state a claim upon which relief may be granted.

Amgen had alleged before the U.S. District Court for the District of Delaware that Coherus' biosimilar medicine CHS-1701 infringed on its patents covering the medicine Neulasta, which is also known as pegfilgrastim.

The drug helps in the growth of new white blood cells, which protects against the risk of infection following chemotherapy. It helped generate $4.53 billion in 2017 revenues for Amgen, including $3.93 billion from the U.S. alone.

Coherus has been looking to market a cheaper version of the medicine, though the U.S. Food and Drug Administration has asked the company to provide additional data before it can approve the biosimilar. The regulator's rejection of its biologics license application for CHS-1701 prompted the company to cut its workforce by about 30%.

The company also expects the European Medicines Agency to make a decision on its application for CHS-1701 sometime later this year.